Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
A step in the right direction, is good to notice. Though only a minor step, (small rise in stock price)yet a huge step in revenue and credibility in the open market. I see the momentum increase more coming trading days, we are still VERY undervalued, by all numbers.
I wonder if Chris would accept a buy-out tomorrow? If so, how would he value it?
Well, the experts would come up with a minimum sum for him I guess With a company structure like this, the patent portfolio etc, it`s a bit more uncertain how to value it. He as biggest shareholder, would not be happy to accept less then 3 dollar a share is my guess.
With the coming uplisting in a couple of months, 500% revenue increase (for now) and a new patent approved for the 340 million EU market and so on... things can set of quickly now with gaining momentum.
GLTA fellow traders and investors.
PRESSRELEASE TODAY; Lexaria Proprietary DehydraTECH-Enabled CBD Powders Business Growing Faster than Expected
Growth now expected to exceed 500% from fiscal Q4 2020 to fiscal Q1 2021
Kelowna, British Columbia – October 22, 2020 – Lexaria Bioscience Corp. (OTCQX: LXRP) (CSE: LXX) (the “Company” or “Lexaria”), a global innovator in oral drug delivery platforms, is pleased to announce that it is exceeding expectations for volume of servings of its patented DehydraTECHTM enabled CBD powders, to be processed during the Company’s fiscal Q1 2021 ending November 30, 2020.
On September 23 2020, Lexaria announced it had received purchase order commitments for the current quarter (September 1 – November 30) for approximately 4.4 million CBD servings of DehydraTECH-enabled CBD powders. Processing rates have exceeded expectations: as of October 21, Lexaria has already processed approximately 4.2 million servings and now has confirmed purchase orders to process a total of over 8.0 million servings during the current quarter.
The new estimate represents over 500% volume growth from approximately 1.2 million CBD servings processed in the Company’s fiscal Q4 ended August 31, 2020, (all figures unaudited) which itself reflected growth of 71% from fiscal Q3, 2020. A serving generally ranges from 10mg to 25mg of CBD each, utilizing the Company’s DehydraTECH patented processes.
If existing activities and conditions continue, Lexaria’s expectations to produce at least 56 million servings during the calendar year 2021, driven by the communications of existing customers, may prove to be conservative. These indicative orders do not include any additional demand from prospective future clients.
Lexaria’s business divisions includes both technology licensing wherein corporate licensees implement DehydraTECH under license within their own facilities under royalty agreements and which generate our most profitable revenue streams; and also B2B operations where clients purchase pre-processed DehydraTECH CBD-powders manufactured at a Lexaria-contracted GMP-certified food facility for shipment back to the client for integration into their final product formats. Fees payable to Lexaria include a combination of manufacturing charges as well as royalty and trademark fees.
The Company continues to caution that it cannot control the ability of third parties to fulfil their own business expectations and, as such, does not express any opinion on the ability of its corporate customers to meet their own targets.
About Lexaria
Lexaria Bioscience Corp.’s (OTCQX: LXRP, CSE: LXX) proprietary drug delivery technology, DehydraTECH™, improves the way active pharmaceutical ingredients (APIs) enter the bloodstream by promoting healthier oral ingestion methods and increasing the effectiveness of fat-soluble active molecules, thereby lowering overall dosing. The Company’s technology can be applied to many different ingestible product formats, including foods, beverages, oral suspensions, tablets, and capsules. DehydraTECH increases bio-absorption by up to 5-10x, reduces time of onset from 1 - 2 hours to minutes, and masks unwanted tastes for orally administered bioactive molecules, including anti-virals, cannabinoids, vitamins, non-steroidal anti-inflammatory drugs (NSAIDs), nicotine, and other molecules. Lexaria has licensed DehydraTECH to multiple companies including a world-leading tobacco producer for the development of smokeless, oral-based nicotine products and for use in industries that produce cannabinoid beverages, edibles, and oral products. Lexaria operates a licensed in-house research laboratory and holds a robust intellectual property portfolio with 18 patents granted and approximately 60 patents pending worldwide. For more information, please visit www.lexariabioscience.com.
INVESTOR CONTACT:
ir@lexariabioscience.com
Phone: 866-221-3341
(continue from previous posting)
Good news and progress, this is what we want. "European patent number 3164141 will be published in the European Patent Bulletin of November 11, 2020 entitled “Food and Beverage Compositions Infused With Lipophilic Active Agents and Methods of Use Thereof” and includes claims for improved oral delivery of cannabinoids, nicotine, non-steroidal anti-inflammatory drugs (NSAIDs) and vitamins.
This is significant; European Patent Bulletin is something of a bible to biotech and pharma industry in Europe. Meaning all in the sector will know this at November 11 (at the latest). With both food and beverage (among others) applications, the LXRP technology will get attention in those markets - with a patent protection! Other markets mentioned are also a possibility, though often longer process to monetize IMO.
Maybe the most important; "Priority is granted to certain dates in 2014 and 2015, strengthening Lexaria’s IP claims compared to more recent competitors. This represents the first patent issuance in Europe under Lexaria’s first patent family." Again... with evolving DehydraTECH formula, Lexaria has a NEW POSITION; Stronger and updated formula, more diversified to different customers needs - with more applications - and now Patented in a 340 million people market. This can be a game changer.
"Lexaria currently has 18 granted patents (including nine granted in the US), along with approximately 60 patent applications pending throughout the world. The granted patents cover delivery of cannabinoids, NSAIDs, nicotine and fat-soluble vitamins. Pending patents are for the delivery of many antiviral drugs, human hormones such as testosterone and estrogen, phosphodiesterase inhibitors and more."
One (1) - is all it takes; if only one major company or conglomerate want to own/buy(license one of the patents, we will be looking at millions; cash/royalties and or other way of payment that will take Lexaria Bioscience to a international player in the biotech sector.
NEWS RELEASE: 10/21/2020
Lexaria Bioscience Granted First European Patent for DehydraTECHTM Technology.
New patent includes method of treatment claims for a broad range of disease conditions including use of:
cannabinoids to treat cardiac conditions such as hypertension and neurological diseases such as Alzheimer’s and Parkinson’s
cannabinoids to treat metabolic disorders and substance abuse and addictions
nicotine to treat tobacco dependence/addiction and neurological diseases
NSAIDs to treat a host of conditions involving pain, fever and inflammatory states
vitamins to treat conditions such as ataxia related to certain vitamin deficiencies
Kelowna, British Columbia – October 21, 2020 – Lexaria Bioscience Corp. (OTCQX: LXRP) (CSE: LXX) (the “Company” or “Lexaria”), a global innovator in oral drug delivery platforms, is pleased to announce that it is receiving its first-ever granted patent in Europe related to its DehydraTECHTM Technology.
European patent number 3164141 will be published in the European Patent Bulletin of November 11, 2020 entitled “Food and Beverage Compositions Infused With Lipophilic Active Agents and Methods of Use Thereof” and includes claims for improved oral delivery of cannabinoids, nicotine, non-steroidal anti-inflammatory drugs (NSAIDs) and vitamins.
In addition, this patent includes important method of treatment claims for a broad range of disease conditions including use of:
cannabinoids to treat cardiac conditions such as hypertension and neurological diseases such as Alzheimer’s and Parkinson’s;
cannabinoids to treat metabolic disorders and substance abuse and addictions;
nicotine to treat tobacco dependence/addiction and neurological diseases;
NSAIDs to treat a host of conditions involving pain, fever and inflammatory states; and,
vitamins to treat conditions such as ataxia related to certain vitamin deficiencies.
Priority is granted to certain dates in 2014 and 2015, strengthening Lexaria’s IP claims compared to more recent competitors. This represents the first patent issuance in Europe under Lexaria’s first patent family.
Lexaria intends to validate and nationalize this patent in many major European countries, significantly expanding our global reach. This patent is a significant addition to the Lexaria intellectual property portfolio, and toward Lexaria’s first formal patent protection across major European nations covering a population of roughly 340 million people.
“We’re very pleased to be awarded our very first European patent grant as we’re continually working to expand both the geography where Lexaria’s intellectual property is protected under law, as well as expand the scope of business possible,” said Chris Bunka, Lexaria Chief Executive Officer. “The receipt of this patent grant is timely in that we have recently forged new relationships in Europe where a number of countries have very progressive markets for the oral delivery of active substances including nicotine and more, supporting our commercialization efforts.”
Lexaria currently has 18 granted patents (including nine granted in the US), along with approximately 60 patent applications pending throughout the world. The granted patents cover delivery of cannabinoids, NSAIDs, nicotine and fat-soluble vitamins. Pending patents are for the delivery of many antiviral drugs, human hormones such as testosterone and estrogen, phosphodiesterase inhibitors and more.
About Lexaria
Lexaria Bioscience Corp.’s (OTCQX: LXRP, CSE: LXX) proprietary drug delivery technology, DehydraTECH™, improves the way active pharmaceutical ingredients (APIs) enter the bloodstream by promoting healthier ingestion methods and increasing the effectiveness of fat-soluble active molecules, thereby lowering overall dosing. The Company’s technology can be applied to many different ingestible product formats, including foods, beverages, oral suspensions, tablets, and capsules. DehydraTECH increases bio-absorption by up to 5-10x, reduces time of onset from 1 - 2 hours to minutes, and masks unwanted tastes for orally administered bioactive molecules, including anti-virals, cannabinoids, vitamins, non-steroidal anti-inflammatory drugs (NSAIDs), nicotine, and other molecules.
Lexaria has licensed DehydraTECH to multiple companies including a world-leading tobacco producer for the development of smokeless, oral-based nicotine products and for use in industries that produce cannabinoid beverages, edibles, and oral products. Lexaria operates a federally licensed research laboratory and holds a robust intellectual property portfolio with 18 patents granted and approximately 60 patents pending worldwide. For more information, please visit www.lexariabioscience.com.
Some thoughts on the article; first, Ted is not just anybody, he knows the topic and is a smart well educated (MBA, CFA) insider.
"It may be a strong indication that Altria has fomented a corporate culture that is inconsistent with modern standards of acceptable behavior and business success." - interesting comment. Maybe this is what it actually boils down to? Chris Bunka don`t deserve any disrespect full BS, big cooperation or not. Mutual respect goes a long way; maybe we will see a new better deal further ahead.
Chris; "In what amounted to a $1 million research project funded by Altria, we think the scientific work on our technology was an absolute success. LXRP learned a lot about the technology and have already deployed that knowledge into the current DehydraTECH™ formulation to improve it for nicotine, other applications and our intellectual property portfolio. So it was a very worthwhile experience that produced extremely valuable, tangible results."
This is the professional response to what went down; the ability to see the benefits and long term value - especially with uplisting within 2-3 months. Getting access to big pocket players on a major stockexchange is a milestone
"We are in the manufacturing stage and after that there is a lot of testing that has to take place to make sure DehydraTECH™ meets various standards. We will make delivery sometime in November and that’s when BATS’ analysis will start." Manufacturing, check. Delivery next month, check. Taken this far already, the BAT collaboration has moved quick! Look out for test results and a signed deal, it`s clear that BAT is moving this to market as fast they can.
I will finish here, though encourage all shareholders and other interested parties, to read the interview with Chris (again). He is refreshingly open and clear; this gives a strong indication that Lexaria Bioscience has a bright future.
Let’s Toke Business --- The Commerce of Cannabis --- By Ted Ohashi MBA, CFA
Week ending October 16, 2020
The following is a recent interview Ohashi conducted with Chris Bunka, CEO of Lexaria Biosciences LXRP
In recent weeks, I have been talking about a recovery in the cannabis stock market and it looked like one was getting underway. But along came Aphria last week with a disappointing earnings report and it all came crashing down.
Monday of this week will be the second anniversary of legal adult-use cannabis in Canada. Much of what I have been talking about above reflects how bumpy the road has been for operators over the past two years. 5 Investors have had even a more difficult time as the current bear market is closing in on the three year mark and has carried most indexes back to the levels that prevailed some six years ago. But let’s not forget there has been real progress over the past few years and cannabis now contributes $9 billion a month to the Canadian economy. There are taxes being generated as a result at a time when government spending is rocketing up and government revenues have been declining. Let’s hope the next two years are better for cannabis operators and cannabis investors.
Lexaria Bioscience (CSE: LXX) (OTCQX: LXRP) had disappointing news regarding Altria not proceeding to Phase 2 of their research agreement. As I said, I thought the market would initially take this as bad news but might eventually figure out it is all for the good. See my summary of a chat with CEO Chris Bunka below
My personal reaction to this news is if Altria was a person, this is extremely disrespectful behaviour. Yet what does Altria have to be condescending about? This is the company that invested US $12.8 billion to acquire 35% of vape market leader Juul less than two years ago that is proving to be a major disaster.
In less than a year, Altria was forced to take a US $4.5 billion write down in that investment and it may not be over yet. Even for a Fortune 500 company that’s a major hit. It may be a strong indication that Altria has fomented a corporate culture that is inconsistent with modern standards of acceptable behavior and business success.
My most important question for Bunka regarding Altria was “Did you come out of it ahead of where you went into it?”
His answer was “Very much so.” In what amounted to a $1 million research project funded by Altria, we think the scientific work on our technology was an absolute success. LXRP learned a lot about the technology and have already deployed that knowledge into the current DehydraTECH™ formulation to improve it for nicotine, other applications and our intellectual property portfolio. So it was a very worthwhile experience that produced extremely valuable, tangible results.
We then had a discussion of other projects that LXRP is engaged in.
British American Tobacco p.l.c. (London Stock Exchange: BATS) is still in the early stages but we are certainly on schedule. We are in the manufacturing stage and after that there is a lot of testing that has to take place to make sure DehydraTECH™ meets various standards. We will make delivery sometime in November and that’s when BATS’ analysis will start.
LXRP cannot disclose what is being manufactured for them except to say Altria wanted to test the formulation we used in the 2018 animal studies and BATS will be working with a newer version and management is very happy about that.
The current recipe is one or two generations advanced and far superior in our view. I think it is possible we will know something before the end of the year but that would be the earliest. It is more likely we are looking at the early part of 2021.
The Up-Listing Process: this project is underway and Bunka reports some very important progress was made recently. We have been held up a couple of weeks but it is still very possible that it will be done by December.
Based on the timing we may have to make some decisions as to whether we want to be dealing with this during the Christmas holidays but it is very much in play. There is nothing I’m aware of that would be a hurdle to making a December date,but realistically, we have January as our fallback position.
The lawyers are working on the registration statement and there are multiple other matters to be done but everything is proceeding pretty much as expected.
The CBD products: it is difficult to talk about the revenue potential of this product. LXRP has announced an order for 4.4 million servings that will be fulfilled in the quarter ended November and verbal orders of approximately 56 million servings for calendar 2021. There are competitive issues to think about as well as normal business matters such as relationships with customers. There are different approaches that impact prices and costs:
1. Some customers that want beverages that involves making the powders and emulsifying them into a concentrated version in preparation for being placed into beverages. The work and costs in this case are substantially higher.
2. Making the powder for the consumer to add to their beverage of choice is considerably less work and less costly.
3. Then there are product formats that are somewhere between the 1. and 2. 4.
4. The revenue potential for 1. above might be, for example, 1 while the revenue potential for 2. above will be .1 while point 3. would fall somewhere between the two. In actuality, the revenue potential could be as low as $.03 per serving and as high as $.85 per serving. So the makeup of our order book can make a difference that will produce a result that is orders of magnitude higher or lower in revenue.
5. Outside of the DehydraTECH™ formulation, for some customers we do no further “manufacturing” and for others we do quite a lot. So for LXRP, we make a royalty-type return on the sales of our technology that is very high margin and on the manufacturing, a relatively low gross margin of say 20% or perhaps slightly more. So our profit margin is going to range from something like 20% to as much as 95% if it is mainly a royalty payment.
We referred a couple of years ago to a report from the American Dental Association that something in the range of 90% of the drinks you can buy at a 24-hour type of store are acidic. The manufacturers of such drinks such as Coca Cola or Red Bull add acidity to their drinks because organisms can’t grow and/or survive in an acidic beverage. So they can extend the shelf life of their drinks to many months by making them acidic.
But there is a huge problem with acidity with cannabis beverages because THC, for example, breaks down. So how do you get stability in an aqueous solution? Everyone knows how to do it but it’s difficult, it’s expensive and it doesn’t last 12 months. Lexaria doesn’t think making cannabis beverages is worth it and at the end of the day it’s going to be really hard to make a profit. But if you talk to people in the cannabis beverage industry today, they can’t accept this because they have invested hundreds of millions and perhaps billions into cannabis beverages.
So LXRP thinks the mix-and-serve approach is the way of the future, and I agree with Lexaria on this.
If I prefer Diet Coke to Diet Pepsi, when it comes to a cannabis beverage, I want Diet Coke. I certainly don’t want the equivalent of a no-name cola as my cannabis cola drink. That’s what the LXRP CBD powder provides. If it’s coffee or tea or beer or wine or an energy drink or even water, I want what I normally drink as a consumer. I have seen it and it is no more difficult that opening a package of sweetener and adding it to your coffee. Not only that you don’t need to restrict its use to beverages. You can add it to a candy, a protein bar, whatever you want.
Projects with anti-viral, COVID medicines. The animal anti-viral testing is underway and we are hoping for results that we can release by Christmas. With the animal study, we are looking for:
1. The most important thing is can we get more of the anti-viral drug into the bloodstream with our technology than without?
2. The second most important thing is does the DehydraTECH™ change the level of toxicity or create adverse effects compared with the non-DehydraTECH™ results?
3. The third is how quickly does it get into the bloodstream?
The results of this study are used as inputs prior to receiving approval for the human study, in other words, did the animals die, were there adverse effects, and so on? We also have to explain at this point and make our case for what we are trying to accomplish. To get this in place we’re looking at mid-2021 or the second half of next year. Everyone is aware of the work going on in the search for a vaccine or the preventative side of things. But there is also as much or more work being done on helping people once they have it. Both will always be needed.
If and when we have a vaccine, let’s say 70% of the people will take it and 70% of those people don’t get sick. That’s 49%. That still leaves around half the population that might get sick. That’s where we are targeting our efforts. Treating those people. That will never disappear. It’s like the flu shot that many people take. Many of them don’t get the flu but some do and those who didn’t get a flu shot might get it as well. Those people still go to the doctor or pharmacist or use over-the-counter medicines to treat their symptoms.
Conclusion: The market clearly interpreted the news from Altria negatively as I suggested it would if this was the eventuality. But based on the market action, I believe at a level of around CA $.20 to $.25 per share for LXX or US$.15 to $.20 per share for LXRP, the stock is oversold. This means, future developments should be accretive to the stock price from its current valuation. Between now and the end of the calendar year, there are three events that could produce a positive response in the markets. First is the up-listing that is underway and mainly under the control of the company.
If it proceeds as I expect it will, Lexaria shares will be exposed to a very large group of new, prospective investors that are more inclined to invest in a pharmaceutical/technology company. This is prospectively promising for investors. Second, there is some possibility that there will be a positive response from British American Tobacco although Bunka suggests it is more likely to be January/February 2021. Third, the results from anti-viral testing on animals is likely to be known in December. Again, this associates LXRP with COVID-19 and this will develop further moving forward. As a result, I believe LXRP has outstanding prospects from current levels for existing shareholders or new investors.
Source: Corporate news email letstokebusiness@gmail.com
LXX.CN - CBD bioavailability and metabolic removal for best result.
When consumers take CBD orally (as a tincture, drink, capsule, gummies, foods, etc), it has the lowest bioavailability of any delivery method. As little as 6% of CBD reaches its goal when taken on an empty stomach. As a comparison, bioavailability of inhaled CBD (through vaping) is about 31%.
The main reason for its poor uptake is that CBD is fat-soluble (not water-soluble), and this makes it hard for the body to absorb it. Its slow absorption through the intestinal wall means that the stomach’s digestive enzymes and acids destroy much of the CBD before absorption through the intestines and the liver (known as “first-pass metabolism”).
In this article, we summarize the available evidence regarding the bioavailability of CBD related to its gastrointestinal absorption, presystemic elimination, and its susceptibility to metabolic drug interactions.
The biopharmaceutical properties of CBD
In biopharmaceutical terms, CBD is a “class 2 compound”, meaning that it has very low water solubility and the body’s metabolism easily eliminates it in the gut. Low-water soluble substances are usually highly soluble in fats (lipophilic). Therefore, experts recommend to take class 2 compounds with a high-fat meal to increase their solubilization in the gut.
In the case of the FDA/EMA approved CBD medicine, the oral CBD solution has a sesame-oil-base to help overcome the poor bioavailability. Regardless, it still only achieves 6 to 19% bioavailability after taking the drug in a fasting state.
When consumers take CBD with a high-fat meal (840–860 calories), plasma CBD concentration dramatically increases 4.9-fold. In addition, taking CBD with a high-fat meal not only increases bioavailability, but also reduces the variability of absorption seen between different individuals.
As such, the large variability in absorption (empty stomach vs. with a high-fat meal) observed could lead to different CBD effects if taken inconsistently around meal-times.
CBD bioavailability and dose-dependence
Once CBD enters the bloodstream, the liver acts to metabolize and convert it into a form that can be easily transported and excreted. However, CBD is a “high-clearance drug”, meaning that the liver extracts and removes about 70–75% of it in the first pass before CBD could reach the systemic circulatory system.
The bioavailability of CBD is also dose-dependent, and we see a decrease in bioavailability at extremely high doses (>3000 mg). This is primarily due to CBD’s poor water solubility, which limits its rapid absorption. Fortunately, the effect is less pronounced in doses in the approved range (10 to 20 mg/kg/day).
How can CBD bioavailability be improved?
With the liver being so efficient in removing CBD, researchers have looked to increase the gastrointestinal absorption of CBD to improve its overall bioavailability. By adding lipids (e.g. oils) to the formulation increases CBD bioavailability by 2.5 times compared with no lipids added.
Scientists have also found that the simultaneous addition of lipids substantially improves CBD bioavailability by stimulating/activating the intestine lymphatic transport system. As such, this assists in enhancing CBD uptake to over 30% uptake of CBD (almost on par with vaping).
Scientists speculate that this different route of absorption may also reduce or avoid the liver’s metabolism of CBD. Lymph flows from the gut walls to the mesenteric lymph nodes and then via the mesenteric and thoracic ducts into the systemic circulation. As such, CBD dissolved in the lymph bypasses the liver’s first-pass metabolism and removal, and thus increasing bioavailability.
A further study noted that the main compound produced after the first-pass metabolism is 7-hydroxy-CBD, which still maintains some of CBD’s beneficial properties. Therefore, measures of CBD bioavailability (post-liver-metabolism) may, in fact, underestimate CBD’s activity still present in the circulation.
In addition, due to its lipophilic properties, taking CBD regularly can result in the accumulation of CBD in the body’s fatty-tissues for up to 2–3 weeks after oral ingestion. This CBD is more slowly released back into the circulation and via the liver for elimination.
[ b]Lexaria Bioscience Corp’s proprietary drug delivery technology, DehydraTECH™, improves the way active pharmaceutical ingredients (APIs) enter the bloodstream by promoting healthier ingestion methods and increasing the effectiveness of fat-soluble active molecules, thereby lowering overall dosing;.
LXX,CN IN FREE REPORT SAMPLE (among others)
Legalized Cannabis Market Excellent Growth 2020 Top Key Players- Aurora Cannabis Inc. Aphria Inc. Canopy Growth Corporation MedReleaf Corp The Cronos Group
https://www.barchart.com/story/stocks/quotes/LXX.CN/overview/438048/legalized-cannabis-market-excellent-growth-2020-top-key-players-aurora-cannabis-inc-aphria-inc-canopy-growth-corporation-medreleaf-corp-the-cronos-group
https://straitsresearch.com/report/legalized-cannabis-market/request-sample (sample application)
Reflections on the quarterly report and revenue streams; Due to the pandemic of Covid-19, most businesses has been hurt, more or less. Lexarias goal (see Chris letter to shareholders, dec 2019) was a 100% increase in revenue - year to year. Though we now know it was a 70% increase on quarterly basis, it`s not to bad, giving the circumstances with the pandemic - and a 1,3 million dollars cash in the bank today.
448000 dollars (as I recall) is roughly 150000/monthly. Is close to 2 million dollars/yearly - if we assume this quarter is about a average number. It`s not a big win, though no disaster either. Giving the deals are growing yearly (especially Cannadips CBD deal), we might reach the 100% goal by next year.
The advantage Lexaria has to many other companies, is that it has diversified to 4 independent divisions = less risk for the overall company. Another is the CEOs major shareholder position; we know he is MOTIVATED to grow "his" company!
Partner Boldt Runners Brings Tobacco Executive.
https://hightimes.com/business/cbd-company-bo...tive-team/
Given this is (for now) the biggest revenue stream, it`s strong news!
LXRP Revolutionizing Drug Delivery Platforms: CEO interview -
LXX.CN - Molecule Signs Agreement with Hill Street Beverage Company Inc. to Produce Cannabis Infused Beverages.
https://www.barchart.com/story/stocks/quotes/...-beverages
Brian Quigley former Altria executive is board member to LXRP and advisor to Cannadips ... seems too odd to not be planned... the question is what is the long term plan - and will/was Lexaria able to navigate to take full advantage in this now active deal?
Time will show - let`s remind ourself, Lexaria has been on these low levels earlier; and then suddenly make a 400% jump on a single trading day. Giving Chris is the largest shareholder, I think supporting him is in the best interest of all shareholders.
Let`s not forget what he said in a interview; " yes, it`s a bit difficult to have a talk, when you have a strong partner as Altria. We came 3 people from Lexaria and on the other side of the table sits about 20 people from Altria."
All shareholders best interest is backing Chris in any way they can - whatever you think and feel; this is the right thing to do for protecting your investment. This is the time to unite behind the Lexaria management, they need us to.
LXX.CN Advance Antiviral Test With DehydraTECH.
Lexaria Bioscience Advances Antiviral Research Initiative Using
DehydraTECH™
https://virtual-strategy.com/2020/10/13/lexaria-bioscience-advances-antiviral-research-initiative-using-dehydratech/
Thx Kgem, glad to see you on the board my friend. Who knows... maybe some more Lexaria fans join? I encouraged/sugggested/gave a option to other Lexaria investors yesterday, on the other Lexaria board.
Some thoughts today; People makes the business; overview.
When in doubt (I was the day before), it can help to remind, what and who was I investing in?
Reading the overview and even more - each one behind Lexaria Bioscience short biography - have made me see new insights and man up again.
https://www.lexariabioscience.com/about/#overview
Wish you all a good sunday.
AlexUlf
Good Post Alexulf. Lexaria has many irons in the fire, and if just one strikes, we are off to the races. I like the idea that companies in tobacco (five majors), big pharma (pretty much all majors), beverages (alcohol, sweet and sparkling water), candies and edibles, and finally CBD and THC products. I am not certain if I missed anything, but you get the idea. The future is wide open for DehydraTech adoption in hundreds of products and scores of industries.
Oversold - Trend Reversal; see chart and Barchart technical opinion.
https://www.barchart.com/stocks/quotes/LXX.CN/overview
It was a negative feeling yesterday... though one day later, I have recover.
As a matter of fact, when I start analyse the new situation, it could benefit LXRP.
Not to pretend I don`t miss the Altria 11M - but this gives Lexaria space to monetize other possibilities within it`s 4 divisions business model. Like Pharma.
Going over my research notes again, I see the Pharma division as the primary goal, in terms of revenue and profit. Pfizer and others have expressed interest in Lexaria Bioscience.
I can also see a conglomerate as BAT, give a buyout proposition. With it`s many applications in it`s businesses, it could benefit greatly of the technology.
Rome was not built in a day , to sell now would be a BIG mistake. Within this year, we will climb up again. Maybe a new 30% run (without dip) next?
What`s your opinion, fellow trader/investor? Share your thoughts on the board.
DehydraTECH’s in its traditional format has been used commercially by the Company since 2014; and by the Company’s technology licensees since 2016. Lexaria has consistently introduced leading innovation for oral cannabis formats such as capsules, beverages and edibles, with a focus on the consumer experience as measured by qualities such as taste, rapidity of onset and offset, and reliability of effect. Unique among the cannabis industry, DehydraTECH has proven itself equally transformative in other sectors such as the nicotine industry where Lexaria has licensed its technology to one of the largest nicotine products companies in the world.
The new Enhanced DehydraTECH seems particularly adept at delivering previously unreachable quantities of CBD across the blood brain barrier and into brain tissue; more so than even the most advanced nanotech as previously reported utilized in these studies. Since most human receptor cells of the CB1 variety and otherwise that are associated with the psychotropic effects of cannabinoids are located within the brain these findings significantly expand upon the power of Lexaria’s technology to reach the target site of action for these purposes.
With this new innovation, Lexaria is establishing new performance thresholds for drug delivery technology, with tested performance of 8x (blood plasma) and more than 19x (brain tissue) of generic industry formulations. The Company intends to perform further studies to fully characterize Enhanced DehydraTECH and will work throughout the year to optimize implementation into the best product applications for use by its licensees.
The animal test results announced to date have led to additional new patent applications based on the positive performance results achieved. The specific nature of enhanced DehydraTECH shall remain undisclosed for proprietary reasons until the new patent filings are published. Although the current tests were limited to CBD absorption, Lexaria expects knowledge from the current innovation to apply equally to tetrahydrocannabinol (THC) as well to enhance formulation innovation for nicotine and various pharmaceutical compounds already named within the Lexaria patent suite.
The future indeed does look bright for Lexaria's Enhanced DehydraTech technology
Ok, 2 days to go, then we know. In case you want to follow the OTC Lexaria trade live;
https://www.otcmarkets.com/stock/LXRP/quote
Reminder; 7 days, 8 of october, ALTRIA DECISION; meanwhile...“Altria has the option to acquire 100% ownership interest in Lexaria Nicotine commensurate with then-current fair market value. Lexaria Bioscience has not sold or optioned any of its own equity.”
If the payment get`s done as well (11 or 14 million U S dollars, depending on source) we would get a rise in the stockprice; though hard to say in percentage, how much it get`s valued by the market. These millions would be a relative high percentage of the low valued Lexaria Biotech stock today.
The Gigantic Potential With BAT... I choose to lift this again, since it seems not have got so much attention (in media). To put it simple; Imagine MULTIPLE type of products... 11 million salespoints/stores etc... ALL Over the world.
Tenbagger stock over a night or a week is not impossible at all, do the math.
Lexaria Bioscience Announces R&D Agreement With British American Tobacco
ACCESSWIRE - Mon Aug 31, 3:02PM CDT
KELOWNA, BC / ACCESSWIRE / August 31, 2020 / Lexaria Bioscience Corp. (OTCQX:LXRP)(CNSX:LXX.CN) (the "Company" or "Lexaria", a global innovator in drug delivery platforms, announces that it has entered a research and development ("R&D" framework agreement with British American Tobacco (Investments) Limited ("BAT" to investigate Lexaria's technology for potential use in nicotine products.
R&D work under the Agreement will be paid for by BAT.
"Lexaria is pleased to work with British American Tobacco on these research and development activities," said Chris Bunka, Chief Executive Officer of Lexaria, who is also responsible for the accuracy of this news release.
The Agreement does not contemplate development of oral nicotine consumer products in North America, given Lexaria's existing North American relationship with a leading United States-based tobacco company. The Agreement is expected to be completed within six months, though provisions exist to extend the Agreement if required.
About BAT
British American Tobacco is a leading, multi-category consumer goods business, established in 1902. BAT's purpose is to build A Better Tomorrow by reducing the health impact of its business through offering a greater choice of enjoyable and less risky products for its consumers. British American Tobacco is one of the largest tobacco companies in the world with products sold in over 11 million locations across more than 180 countries.
Lexaria Receives Conditional Ethics Board Approval for Pilot Human Study Using DehydraTECHTM Technology in Delivering Antiviral Drugs.
https://mail.google.com/mail/u/0/#inbox/FMfcgxwJZJQgZSvnDxsDHWGsnBCDLpFB
LETTER FROM CEO TO SHAREHOLDERS.
This is not new, it`s written in december, so about 8-9 month ago.
Still, if you have not read it - I think you can benefit and get more knowledge how management/CEO is seeing Lexaria Biotechs development.
https://www.lexariabioscience.com/news/lexaria-bioscience-ceo-discusses-strategic-outlook/
WALL STREET JOURNAL ANALYST ON THE LEXARIA BIOTECH STOCK;
https://www.wsj.com/market-data/quotes/LXRP/research-ratings
Within 2 weeks the coming Altria decision and opportunity, reflecting from the statement posted from the the Altria vision; I include a part from the promotion of the IR firm as well.
"The tranche trigger activation would initiate a staged payment to Lexaria Nicotine LLC. and enable Altria to retain its current exclusivity in the US market for Lexaria's DehydraTECH™ for oral nicotine delivery purposes.
Altria currently holds an existing minority equity stake and board representation in Lexaria Nicotine LLC. and is titled to a non-exclusive license to use DehydraTECH™ worldwide. Lexaria is expected to benefit from an earlier-defined royalty payment schedule if Altria decides to utilize the technology commercially, regardless of additional R&D results"
Altrias own statement; "The tobacco industry is changing – and for the better. The future of our industry is about innovation, harm reduction and informed consumer choice. With FDA regulation of the tobacco industry in place, we're focusing our tremendous resources and talented people on reducing the risk of tobacco products, while expanding choices for adult consumers".
So, we have a down payment of 11 million US dollars, royalty deal set and the change to actual PARTNERSHIP who will increase it`s equity stake big time... AND get 3 directors on the board = big influence on protecting Lexaria, cause they will be a important part of Lexarias future and protecting the investment equals Altrias best interest.
I see so many potential catalysts that could kick in quickly. Even if only one thing is done, LXRP could approach a dollar in no time at all. It should be noted that Lexaria has one of the largest portfolios of PATENTS involving cannabis in the entire world (perhaps the largest portfolio). So over time, LXRP could easily be a multi-millionaire maker. In my opinion, it would be easy to pump such a stock. However, I don't see where pumping is even necessary. LXRP is a gamble, just like most penny stocks, but this one has a PORTFOLIO of patents to back up its claims. And, the company is not fearful of letting shareholders know what they are actually doing. Refreshing!
Market Watch On Lexaria Biotech Today; buy rating, target price; 1.20 dollars.
https://www.marketwatch.com/investing/stock/l...testimates
Good luck to all.
Amazing... the CBD products (and others) will be acknowledge as the premier and/or PREMIUM within it`s product category. The customer will know it`s processed in a way that is special - and get the maximum of amount on the specific substance (like CBD) to the bloodstream. Scientific evidence (measurable) in sales pitch will make the products fly of the shelf and create the leading brands in each category of it`s industry.
Given the big orders start dropping in (increasing volume/revenue) 2021 can be magic for this penny stock. As they have different ways of sell to each customer, it`s also a great benefit for the B to B model. Adapting to various situations will be a huge gain, to attract more customers in each of it`s 4 divisions. The data and the patents - the intellectual property will be increasingly an advantage.
Please feel free to join with posting, you are most welcome - appreciate also if you give a board mark, thank you.
Given yesterdays announcement; I would go from a "buy" to "strong buy".
Good luck all.
Lexaria Receives Orders for 4.4 Million Servings of DehydraTECH-Enabled CBD Powders;
https://www.accesswire.com/607264/Lexaria-Receives-Orders-for-44-Million-Servings-of-DehydraTECH-Enabled-CBD-Powders
LXRP has come a long way to mitigate risks.
Lexaria Bioscience (OTC: LXRP; CSE: LXX) may be a micro-cap stock, but it plays in the big leagues by signing significant and potentially lucrative deals with multi-billion-dollar businesses. Most recently, Lexaria announced entering into a research and development framework agreement with British American Tobacco Limited (NYSE: BTI) to investigate Lexaria's technology for potential use in nicotine products.
The deal is valuable, and potentially accretive, on at least two fronts. First, BTI will fund all work under the final research and development agreement. And second, as a result of these non-dilutive studies, the results can become valuable assets to Lexaria and its partners. It's a win/win scenario that showcases how the innovative and patented DehydraTECH™ technology can improve the way pharmaceutical ingredients enter the bloodstream. Moreover, this latest R&D agreement further validates the interest in DehydraTECH™ as a potential game-changing platform to meet the needs of fast-changing pharmaceutical and consumer goods sectors.
In particular, the opportunities created from this research agreement can be substantial and come well-backed by an industry giant, British American Tobacco, a 118-year-old tobacco and consumer goods business with products sold in over 11 million locations across more than 180 countries. The company is focused on building "A Better Tomorrow" by reducing its business's health impact by offering a greater choice of enjoyable and less risky products for its consumers. BTI's market cap stood at over $75 billion at the end of August.
Their mission may play directly into Lexaria's strength through the DehydraTECH™ technology. Further, the additional research and development agreements already in place with other billion-dollar companies like Altria Group (NYSE: MO), position Lexaria to create near and long-term shareholder value by identifying and exploiting opportunities born through its innovative platform.
Video Link: https://www.youtube.com/embed/oNUJeOo83EU
The Broad Applications Of DehydraTECH™
The value driver at Lexaria comes through its DehydraTECH™ platform. More than improving the way active pharmaceutical ingredients (APIs) enter the bloodstream, this platform also promotes healthier ingestion methods and increases the effectiveness of fat-soluble active molecules, which, in turn, can be a valuable factor to lowering overall dosing. Also, the technology is not one-dimensional. It can be applied to numerous ingestible product formats, including foods, beverages, oral suspensions, tablets, and capsules. Thus, the opportunities can be nearly endless for its commercial applications.
An example of that reach came last month when the company received ethics board approval from a European university research hospital to conduct an exploratory clinical study using cannabidiol ("CBD" formulated together with its patented DehydraTECH™ technology. The trial will assess blood pressure reduction potential in volunteers with pre-or mild hypertension. According to Lexaria, the study is designed as a double-blinded, placebo-controlled, cross-over pilot study where 24 volunteers (12 males and 12 females, aged 45-70 years) will be randomized to receive a 300 mg dose of CBD with or without DehydraTECH™ formulation enhancement. Dosing will be in oral capsule form across two separate study visits. The primary outcome will be automated measures of blood pressure and heart rate. Secondary outcome measures will include circulating plasma concentrations of CBD and assessing key inflammatory markers associated with cardiovascular disease.
Results from this study are intended to complement its previous clinical research from 2018, as published in the peer-reviewed medical journal "Advances in Therapy." In that study, a single 90mg CBD dose of Lexaria's TurboCBD™ oral capsule provided evidence of lower blood pressure, higher blood flow to the brain, faster delivery onset of CBD into the bloodstream, and larger quantities of CBD within the blood compared to a single 90mg dose of generic CBD in healthy, normotensive volunteers. Additional findings demonstrated a significant 5% reduction in mean arterial blood pressure (MAP) when normalized to end-tidal CO2 at peak blood levels of CBD with Lexaria's TurboCBD™ compared to placebo (95% CI; p=0.016). The trial is designed to evaluate performance in a pre- and mildly hypertensive population more representative of consumers who may benefit from blood pressure control and reduction.
Lexaria expects to have results from the study during the fourth quarter of 2020, with updates provided as the data is analyzed and available. The existing annual market for blood pressure control is roughly $24 billion but many of the drugs currently in use are plagued with unwanted and sometimes dangerous side effects. There is a real opportunity for Lexaria’s patented processing of CBD to enter this market, after suitable testing and evaluation.
Milestone Achieved In Completing Altria Ventures Phase I Study
With a potential catalyst in the near-term from its CBD study, Lexaria is now working to capitalize on its previously announced milestone. That event came at the conclusion of a Phase I research and development program with Altria Ventures Inc. (NYSE: MO) to evaluate oral forms of nicotine delivery utilizing Lexaria's patented DehydraTECH™ technology. Mainly, that research and development program was initiated to assess reduced health risks of a preliminary DehydraTECH™ oral nicotine formulation relative to combusted tobacco.
The results from Phase I are encouraging. In July, study data released by Lexaria showed that the DehydraTECH™ formulation showed acceptable chemical and microbiological stability and was well-tolerated in a 7-day, repeat dose acute toxicology study in rats. Critical to the safety profile, those results showed no test-article-related effects on survival, macroscopic findings, or organ weights. There were also no test-article-related histopathological tissue findings.
Further, the formulation created no throat burn or irritation issues in an oral pouch or chew formats at standard commercial doses upon small scale sensory analysis in humans. Data also demonstrated the formation of a unique mixture of nanoparticles without creating a covalently linked, new molecular entity construct upon molecular characterization by Canada's National Research Council (NRC). Thus, the formulation is not believed to be preclusive of Premarket Tobacco Product Application ("PMTA" applicability in this respect.
Lexaria noted that after completing the Phase I study, Altria preserved its right to activate the "First Warrant Tranche Trigger," a term defined in the Warrant and Option Agreement dated as of January 15, 2019. The tranche trigger activation would initiate a staged payment to Lexaria Nicotine LLC. and enable Altria to retain its current exclusivity in the US market for Lexaria's DehydraTECH™ for oral nicotine delivery purposes.
Altria currently holds an existing minority equity stake and board representation in Lexaria Nicotine LLC. and is titled to a non-exclusive license to use DehydraTECH™ worldwide. Lexaria is expected to benefit from an earlier-defined royalty payment schedule if Altria decides to utilize the technology commercially, regardless of additional R&D results.
DehydraTECH™ Delivers Speed Of Bio-Absorption
The most notable advantages to utilizing DehydraTECH™ in orally delivered products is that it increases bio-absorption by up to 5-10x, reduces the time of onset from 1-2 hours to 10-20 minutes, and masks unwanted tastes for orally administered bioactive molecules. Those advantages substantially broaden the potential applications of the technology. Examples of molecules tested or currently under investigation using Lexaria's DehydraTECH™ include anti-viral drugs, cannabinoids, vitamins, non-steroidal anti-inflammatory drugs (NSAIDs), nicotine, and other molecules.
Lexaria is also expanding its revenue-generating opportunities. The company has licensed DehydraTECH™ to multiple companies across different sectors, including Altria, where the goal would be to develop smokeless, oral-based nicotine products. Other licensees include companies that produce cannabinoid beverages, edibles, and oral products. To quickly capitalize on market opportunities, Lexaria operates a licensed in-house research laboratory and owns a robust intellectual property portfolio with 16 patents granted and over 60 patents pending worldwide.
That IP portfolio provides the time and protection needed to identify and develop new platform applications. An important and timely opportunity may come in the fight against COVID-19. Lexaria has commenced a program to investigate how the rapid and effective absorption offered by DehydraTECH™ could potentially help the best anti-viral drug candidates in treating the pandemic virus. Updates from that program may also be imminent.
New Deals, Ongoing Studies Set Stage For Strong Finish In 2020.
The stage is set to produce at least one catalyst as interim results from its ongoing CBD trial evaluating blood pressure reduction in patients with hypertension is expected by the end of the year. However, late-breaking news, similar to the British American Tobacco agreement, can come at any time. And as the value of its DehydraTECH™ platform becomes more mainstream, those events are likely to occur.
Moreover, Lexaria is already leveraging established relationships with multiple pharmaceutical, nicotine, and cannabis/CBD companies to create more effective treatments and revenue-generating opportunities. And while the BTI agreement may be one of the new partnerships, the company has stated on occasion that they are in discussions with large tobacco companies to secure additional working relationships by the end of this year. That's a plurality of opportunity.
Investors should also remember that Lexaria has filed to uplist to a more senior exchange, a move that can generate a new level of interest and exposure to investors. That filing occurred in July, making updates on that status another potential catalyst before the end of 2020. For Lexaria, and its investors, combining the sum of the parts may equate to a great opportunity, especially at current price levels.
And while no investment is without risk, Lexaria has been securing important agreements and contracts with some of the world's largest companies. Having deep-pocketed allies is always welcome.
Along with a robust and innovative drug delivery platform, those relationships may play an important factor in positioning Lexaria for near and long-term success.
Visit https://get.ceo3in60.com/lxrp/ for additional insights into Lexaria Bioscience
Buy rating and target price. (buy, target price 1.20 dollars)
https://www.marketwatch.com/investing/stock/l...testimates
Lexaria Bioscience Continues to Grow its Patent Portfolio
Kelowna, British Columbia – September 22, 2020 – Lexaria Bioscience Corp. (OTCQX: LXRP) (CSE: LXX) (the “Company” or “Lexaria”), a global innovator in drug delivery platforms, is pleased to announces that it has received another new granted patent in the USA.
Lexaria has been granted U.S. Patent No. 10,756,180 pursuant to the Notice of Allowance it received from the United States Patent and Trademark Office (“USPTO”) for patent application number 16/497,920 previously announced on April 23, 2020.
This new patent provides patent claims that protect the use of Lexaria's DehydraTECH™ technology together with cannabinoids, nicotine, nonsteroidal anti-inflammatory drugs, or vitamins in mix and serve beverage formats. The patent is entitled “Food and Beverage Compositions Infused With Lipophilic Active Agents and Methods of Use Thereof”. This signifies another addition to Lexaria’s first patent family, under which nine US patents have now been granted.
Lexaria has also responded to patent office queries in Europe, India, Mexico, Australia, USA, Japan and Canada in recent weeks and although the Company does not expect all its applications to be successful, it is optimistic of additional patent grants in some of these locations soon.
Lexaria currently has 17 granted patents, with 9 granted in the US and 8 in Australia, along with roughly 60 patent applications pending throughout the world. The granted patents cover delivery of cannabinoids, NSAIDs, nicotine and fat-soluble vitamins. Patents are pending for the delivery of antiviral drugs, human hormones such as testosterone and estrogen, phosphodiesterase inhibitors and more.
About Lexaria
Lexaria Bioscience Corp.’s (OTCQX: LXRP, CSE: LXX) proprietary drug delivery technology, DehydraTECH™, improves the way active pharmaceutical ingredients (APIs) enter the bloodstream by promoting healthier ingestion methods and increasing the effectiveness of fat-soluble active molecules, thereby lowering overall dosing. The Company’s technology can be applied to many different ingestible product formats, including foods, beverages, oral suspensions, tablets, and capsules.
DehydraTECH increases bio-absorption by up to 5-10x, reduces time of onset from 1 - 2 hours to 10 - 20 minutes, and masks unwanted tastes for orally administered bioactive molecules, including anti-virals, cannabinoids, vitamins, non-steroidal anti-inflammatory drugs (NSAIDs), nicotine, and other molecules. Lexaria has licensed DehydraTECH to multiple companies including a world-leading tobacco producer for the development of smokeless, oral-based nicotine products and for use in industries that produce cannabinoid beverages, edibles, and oral products. Lexaria operates a licensed in-house research laboratory and holds a robust intellectual property portfolio with 16 patents granted and over 60 patents pending worldwide. For more information, please visit www.lexariabioscience.com.
LXRP Support Boldt Runners NEW Growth Plan.
Lexaria Bioscience says it supports DehydraTECHTM licensee Boldt Runners' corporate growth initiatives.
https://www.proactiveinvestors.com/companies/...29232.html
Good afternoon, appreciate your board mark, when visiting LXX.CN, thanks. You also have a LXRP (OTC) board. This one is new and need your support.
Continue previous post; Altria/Lexaria collaboration. Been looking in a bit more on the Altria - Lexaria connection, some basics; a link to the director, assigned by Altria to be one of Lexarias directors - https://www.lexariabioscience.com/about/mr-brian-quigley/
Reading his background and skillset again, makes me even more comfortable with my investment. Leave it to you guys know, hope you get some more usefull knowledge about Lexarias main partner for now.
Have a nice weekend.
Some thoughts; Altria got one director on the Lexaria board now, they will have another 2, if they continue and pay Lexaria (11 millions I think)for the rights to use the formula. This decision shall be taken within 2020 by Altria. IF they do... 11 million dollars is a lot, even for Altria. Then one can be pretty sure (?) they are commited to follow up with recent product development and a clear path to market with new products. The fact they then will have 3 directors on the board, also give them significant increasing influence. Lexaria should then; 1. get 11 million dollars, 2,license fees and 3.royalty percentage of Altrias sales. Possible FIRST catalysator, within this year. To have a new signed deal and active continued collaboration, could be a key to strengthen and close now potential further agreements within the 4-division-strategy. (Could possibly also give more credit to get Lexarias approval on Nasdaq application)
In my research on this company, and in what they have to offer, I was astounded to find that they have discovered an entirely new delivery "platform" that can be utilized to deliver cannabis medications that until now was seldom if ever explored.
For example, the reason CBD is taken by eyedropper under the tongue is because the human digestive system breaks down CBD before the body ever has the opportunity to absorb it. What little is absorbed, is only a fraction of what one takes, and that amount varies for every single human being.
Lexaria Biosciences found they could combine CBD with long chain fatty acids thereby by-passing the normal digestive degradation (long chain fatty acids are a normal and natural part of our everyday foods). This delivery approach opens entirely new frontiers for medication delivery, and facilitates nearly full absorption. In effect, Lexaria now has a "platform" that can be utilized to deliver a whole host of products never before considered. The possibilities are endless.
Lexaria Support Licensee, Cannadips CBD, Boldt Runners Corporation
Lexaria Bioscience Supports Corporate Growth Initiatives by its Licensee, Cannadips CBD by the Boldt Runners Corporation.
https://www.barchart.com/story/stocks/quotes/LXX.CN/news/269148/lexaria-bioscience-supports-corporate-growth-initiatives-by-its-licensee-cannadips-cbd-by-the-boldt-runners-corporation
MarketWatch Target Price 1.20 US dollars
https://www.marketwatch.com/investing/stock/lxrp/analystestimates
TURNAROUND IS ON FOR LEXARIA Bioscience Corp/Lexaria Corp.
Lexaria Bioscience Corp (LXX.CN)
0.375 +0.025 (+7.14%) 09/16/20 [CNSX]
QUOTE OVERVIEW for Wed, Sep 16th, 2020Alerts Watch Help
Day Low
0.365
Day High
0.375
Open 0.375
Previous Close0.350
Volume19,950
Avg Vol41,593
Stochastic %K18.89%
Weighted Alpha-60.10
5-Day Change+0.005 (+1.35%)
52-Week Range0.310 - 0.990
since 09/16/19
Most Recent Stories
Lexaria Bioscience Supports Corporate Growth Initiatives by its Licensee, Cannadips CBD by the Boldt Runners Corporation
TheNewswire.ca - Wed Sep 16, 5:25AM CDT
(via TheNewswire)
LXX.CN : 0.375 (+7.14%)
Lexaria Bioscience Announces R&D Agreement With British American Tobacco
ACCESSWIRE - Mon Aug 31, 3:02PM CDT
KELOWNA, BC / ACCESSWIRE / August 31, 2020 / Lexaria Bioscience Corp. (OTCQX:LXRP)(CSE:LXX) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, announces that it has entered a...
LXX.CN : 0.375 (+7.14%)
Lexaria Bioscience to Present at the LD 500 Virtual Conference
ACCESSWIRE - Thu Aug 20, 6:17AM CDT
Company to discuss its Phase I R&D program with Altria Ventures Inc., for oral forms of nicotine delivery utilizing its patented DehydraTECH™ technology
LXRP : 0.2835 (+4.00%) LXX.CN : 0.375 (+7.14%)
Medical Marijuana Market 2020 Industry Size, Growth, Trends, Segments and Cost Structure Analysis Research Report 2028
AmericaNewsHour - Mon Aug 3, 7:25AM CDT
Research Nester published a report titled which delivers a detailed overview of the medical marijuana market in terms of market segmentation by end- user, by product, by application, and by region.
Lexaria Announces 2020 Annual and Special Meeting Results
TheNewswire.ca - Wed Jun 24, 5:15AM CDT
(via TheNewswire)
LXRP : 0.2835 (+4.00%) LXX.CN : 0.375 (+7.14%)
Lexaria Bioscience Applies for NIH Grant for COVID-19 Therapy Studies and Receives New Expanded Health Canada License
TheNewswire.ca - Thu Jun 18, 5:30AM CDT
(via TheNewswire)
LXRP : 0.2835 (+4.00%) LXX.CN : 0.375 (+7.14%)
Medical Marijuana Market To Grow During 2020-28 On Account Of Increasing Adult Patients With Chronic Diseases
AmericaNewsHour - Wed Jun 17, 6:52AM CDT
Research Nester published a report titled which delivers a detailed overview of the medical marijuana market in terms of market segmentation by end- user, by product, by application, and by region.
Marijuana Market Trends, Share, Size, Growth, Supply and Manufacturers Analysis Research Report 2025
AmericaNewsHour - Wed Jun 17, 3:38AM CDT
Global Marijuana Market was valued at USD 17.2 Billion in the year 2017. Global Marijuana Market is further estimated to grow at a CAGR of 22.9% from 2019 to reach USD 88.97 Billion by the year 2025. North...
Barchart Technical Opinion LXRP Lexaria Bioscience Corp.
The Barchart Technical Opinion rating is a 88% Sell with a Weakening short term outlook on maintaining the current direction.
The market is approaching oversold territory. Be watchful of a trend reversal.
KELOWNA, BC / ACCESSWIRE / September 16, 2020 / Lexaria Bioscience Corp. (OTCQX:LXRP)(CSE:LXX) (the "Company" or "Lexaria", a global innovator in drug delivery platforms, proudly supports the corporate growth initiatives underway by its DehydraTECHTM licensee, Boldt Runners Corporation ("Boldt Runners", owners of the Cannadips CBD brand.
Cannadips CBD is the original and leading CBD oral pouch brand in America, and Lexaria's fast acting absorption technology is inside every tin. Boldt Runners is preparing for strong growth through its recent executive appointments, financing, and sales channel expansion. This combination is expected to lead to a large increase in sales volumes over the next 12 months.
Peter Diatelevi is appointed as Boldt Runners new CEO, bringing more than two decades of experience with Altria Corp, leading field sales and sales operations in a number of roles including Vice President Sales Operations. Maura Scott is appointed Chief Sales and Compliance Officer, and was most recently Vice President Northeast Region and led a sales team of 400 people across 13 states for Altria Corp. Case Mandel, former Boldt Runners CEO and co-founder, is now Chairman of the Board and President.
Peter Diatelevi, CEO Boldt Runners commented: "I am excited to join the Cannadips CBD brand and am truly fortunate to be working with such an amazing team and product. I have long believed that providing a viable non-tobacco and non-nicotine dip alternative for adults is an important step forward. The work Cannadips CBD has done on the development of this product is outstanding, and I look forward to working with Lexaria as we continue to develop and implement the technology."
Boldt Runners is fostering growth in sales and manufacturing. The company recently built a new state-of-the-art manufacturing facility in Humboldt County, CA that will allow for expanded production levels of cutting-edge pouching technologies, as well as for future growth. In addition, this licensed facility will soon include the capability of implementing Lexaria's DehydraTECH technologies into infused cannabinoid products.
Cannadips CBD plans continued expansion through its existing relationship with existing and future trade partners and with a strong e-commerce presence, and will be introducing new flavors throughout these networks, including planned expansions to new states.
About Boldt Runners Corporation
The Boldt Runners Corporation is based in the heart of Humboldt County, California. Boldt Runners manufacturers, markets and sells Cannadips CBD - the Original Smokeless Dip Pouch with CBD, which has been built on the same values of quality, craftsmanship, and innovation that have made the Humboldt County region world-famous. Since 2016, Cannadips CBD has been paving the way to a full flavor experience for traditional dippers without tobacco or nicotine. Cannadips CBD comes in five core flavors; American Spice, Natural Mint, Tangy Citrus, Tropical Mango, and Fresh Wintergreen and can be found in over 5,000 stores nationwide. Cannadips CBD is on a growth trajectory and is poised to provide more fantastic flavor and form options for the traditional adult smokeless tobacco consumer looking for alternatives. No tobacco, No nicotine, All flavor. For further information please check out www.cannadipscbd.com.
About Lexaria
Lexaria Bioscience Corp.'s (OTCQX:LXRP)(CSE:LXX) proprietary drug delivery technology, DehydraTECH™, improves the way active pharmaceutical ingredients (APIs) enter the bloodstream by promoting healthier ingestion methods and increasing the effectiveness of fat-soluble active molecules, thereby lowering overall dosing. The Company's technology can be applied to many different ingestible product formats, including foods, beverages, oral suspensions, tablets, and capsules. DehydraTECH increases bio-absorption by up to 5-10x, reduces time of onset from 1 - 2 hours to 10 - 20 minutes, and masks unwanted tastes for orally administered bioactive molecules, including anti-virals, cannabinoids, vitamins, non-steroidal anti-inflammatory drugs (NSAIDs), nicotine, and other molecules. Lexaria has licensed DehydraTECH to multiple companies including a world-leading tobacco producer for the development of smokeless, oral-based nicotine products and for use in industries that produce cannabinoid beverages, edibles, and oral products. Lexaria operates a licensed in-house research laboratory and holds a robust intellectual property portfolio with 16 patents granted and over 60 patents pending worldwide. For more information, please visit www.lexariabioscience.com.
LXX.CN (Lexy) News Article Today - dropping hints with todays PR? Seems a little odd to highlight one of their licensees this way, but Altria might connect the dots
Peter Diatelevi is appointed as Boldt Runners new CEO, bringing more than two decades of experience with Altria Corp, leading field sales and sales operations in a number of roles including Vice President Sales Operations. Maura Scott is appointed Chief Sales and Compliance Officer, and was most recently Vice President Northeast Region and led a sales team of 400 people across 13 states for Altria Corp. Case Mandel, former Boldt Runners CEO and co-founder, is now Chairman of the Board and President.
https://finance.yahoo.com/news/lexaria-bioscience-supports-corporate-growth-102500317.html
Lexaria and Altria has collaborating long now - and Altria is to decide if they want to continue with the project and pay Lexaria some millions if they shall exercise there rights (see Altria deal) or not.
The new deal with BAT, can be a factor in the Altria-Lexaria collaboration. The fact is; 2 of the top 3 (!) tobacco companies is looking to work with and invest in Lexarias technology.
Lexarias hand got even stronger towards Altria, when BAT joined smile. I can see different scenarios of value gain for Lexaria, both in the short and long term. Example; one of the 2 tobacco giants might try to buy Lexaria, to protect the technology and get monopoly on it (many applications).
Time will tell; 50% plus value gain in stock price within 3,5 months
Lexarias 4 most recent Video Interviews 2020.
1. Lexaria signs R&D agreement with British American Tobacco
Lexaria is technology for improved delivery of bioactive compounds.
Introducing Lexaria and DehydraTECH Technology: (introduction video)
https://www.lexariabioscience.com/
PRESSRELEASE TODAY; possibly be a catalyst for tomorrow trade.
https://www.marketwatch.com/press-release/lexaria-bioscience-inks-rd-framework-deal-with-british-american-tobacco-dehydratechtm-platform-provides-growth-tailwind-into-q4-2020-09-14
The Billion Dollar Opportunity; One agreement with Altria (US nr 1 Tobacco company) and now a new one with BAT (international/non-US), Lexaria is in position for a major milestone; the Non-Smoking Nicotine market!
With a setup of the 2 giant companies, Lexaria will very soon go from a minor stock, to a accepted player on Wall Street (see new Investor Relation deal) - despite difficult capital markets, Lexaria has now reached the turning point!
26% insider ownership will start pay off big time... now I guess we will have a short time window with a cheap stock. Though how long? With Uplisting coming up, revenue increasing, a big portfolio of international patents and active collaboration with Fortune 500 companies - Lexarias future looks very bright.
Today trades on 0,27 - any guess from you, what`s it worth 31 of december?
My prediction is it will be above 100% value gain, being conservative
As always, do your own DD, this is only my opinion. Have a nice day guys.
https://www.lexariabioscience.com/
Lexaria signs deal with British American Tobacco!
Lexaria and Altria complete development program (first part)
Followers
|
1
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
50
|
Created
|
09/05/18
|
Type
|
Free
|
Moderators |
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |